HUP0402049A2 - Rekombináns anti-oszteopontin ellenanyag és annak használata - Google Patents

Rekombináns anti-oszteopontin ellenanyag és annak használata

Info

Publication number
HUP0402049A2
HUP0402049A2 HU0402049A HUP0402049A HUP0402049A2 HU P0402049 A2 HUP0402049 A2 HU P0402049A2 HU 0402049 A HU0402049 A HU 0402049A HU P0402049 A HUP0402049 A HU P0402049A HU P0402049 A2 HUP0402049 A2 HU P0402049A2
Authority
HU
Hungary
Prior art keywords
antibody
osteopontin
rheumatism
subject
treatment
Prior art date
Application number
HU0402049A
Other languages
English (en)
Inventor
Toshimitsu Uede
Shigeyuki Kon
Nobuchika Yamamoto
Hirofumi Higuchi
Masaharu Torikai
Yoshiyuki Tokieda
Toshihiro Nakashima
Hiroaki Maeda
Original Assignee
Immuno-Biological Laboratories Co., Ltd.
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno-Biological Laboratories Co., Ltd., Fujisawa Pharmaceutical Co., Ltd. filed Critical Immuno-Biological Laboratories Co., Ltd.
Publication of HUP0402049A2 publication Critical patent/HUP0402049A2/hu
Publication of HUP0402049A3 publication Critical patent/HUP0402049A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A találmány tárgya egy rekombináns ellenanyag, amiben a nehéz láncnakés a könnyű láncnak legalább a konstans régióit humán eredetű régiókracserélték ki, és amely ellenanyag gátolja a kötődést egy RGD-szekvenciát és oszteopontint vagy annak fragmensét felismerő integrinközött, valamint gátolja az SVVYGLR szekvencia és az oszteopontin,vagy fragmense közötti kötődést. Ez az ellenanyag jól használhatógyógyszerként az autoimmun betegségekben és a reuma vagy reumásarthritis kezelésében. A találmány tárgya tehát eljárás autoimmunbetegségek, reuma vagy reumás arthritis kezelésére. Ez az oszteopontinellenanyag jól használható eszköz a reuma diagnosztizálására, és areuma diagnosztizálási eljárásában is. Ó
HU0402049A 2001-09-25 2002-09-25 Recombinant anti-osteopontin antibody and use thereof HUP0402049A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001290700 2001-09-25
PCT/JP2002/009868 WO2003027151A1 (fr) 2001-09-25 2002-09-25 Anticorps recombinant anti-osteopontine et son utilisation

Publications (2)

Publication Number Publication Date
HUP0402049A2 true HUP0402049A2 (hu) 2005-01-28
HUP0402049A3 HUP0402049A3 (en) 2009-04-28

Family

ID=19112969

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402049A HUP0402049A3 (en) 2001-09-25 2002-09-25 Recombinant anti-osteopontin antibody and use thereof

Country Status (16)

Country Link
US (1) US7241873B2 (hu)
EP (1) EP1431310A4 (hu)
JP (1) JPWO2003027151A1 (hu)
KR (1) KR20040048899A (hu)
CN (1) CN100352844C (hu)
AU (1) AU2002332290B2 (hu)
BR (1) BR0213078A (hu)
CA (1) CA2461529A1 (hu)
HK (1) HK1084127A1 (hu)
HU (1) HUP0402049A3 (hu)
MX (1) MXPA04002837A (hu)
NO (1) NO20041225L (hu)
NZ (1) NZ531818A (hu)
PL (1) PL369446A1 (hu)
RU (1) RU2305111C2 (hu)
WO (1) WO2003027151A1 (hu)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234524A1 (en) * 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
CA2461529A1 (en) 2001-09-25 2003-04-03 Immuno-Biological Laboratories Co., Ltd. Recombinant anti-osteopontin antibody and use thereof
WO2004013311A2 (en) * 2002-08-06 2004-02-12 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
JPWO2004103403A1 (ja) * 2003-05-23 2006-07-20 株式会社 免疫生物研究所 免疫担当細胞活性化阻害剤およびその用途
JP4796967B2 (ja) * 2003-11-07 2011-10-19 ヴァーミリオン インコーポレイテッド アルツハイマー病のためのバイオマーカー
PT1721162E (pt) * 2004-02-27 2008-12-03 Hoffmann La Roche Método de avaliação da artrite reumatóide pela medição de anti-ccp e de amilóide a sérica
ES2541683T3 (es) * 2004-02-27 2015-07-23 F. Hoffmann-La Roche Ag Método para evaluar la artritis reumatoide mediante la medición del factor reumatoide y la interleuquina-6
WO2006081171A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
WO2006116793A1 (en) * 2005-05-04 2006-11-09 Australian Stem Cell Centre Limited Selecting, culturing and creating lineage committed hematopoietic stem cells
MY185597A (en) * 2005-09-20 2021-05-24 Avantor Performance Mat Inc Vegetarian protein a preparation and methods thereof
EP2025749B8 (en) * 2006-05-31 2012-05-23 Astellas Pharma Inc. Humanized anti-human osteopontin antibody
JP5399710B2 (ja) * 2006-10-26 2014-01-29 株式会社ジーンテクノサイエンス 細胞外マトリックスタンパク質のアミノ酸配列ｒｇｄに対する抗体およびその製法と用途
CN101680887B (zh) 2007-03-30 2014-06-25 褚圣-贾斯汀公司 测定脊柱侧凸风险的方法
KR100894265B1 (ko) * 2007-06-05 2009-04-21 재단법인서울대학교산학협력재단 골형성 촉진 펩타이드를 함유하는 주입형 골재생재
EP2170960B1 (en) * 2007-07-13 2015-07-29 Bac Ip B.V. Single-domain antigen-binding proteins that bind mammalian igg
HUE034401T2 (hu) * 2007-12-13 2018-02-28 Monsanto Technology Llc Készítmények és módszerek korai terhességi diagnózisra
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
MX2010007515A (es) * 2008-01-11 2010-11-12 Chemo Sero Therapeut Res Inst Anticuerpo antiintegrina a9 humana humanizado mejorado.
WO2009131256A1 (en) * 2008-04-24 2009-10-29 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
SG190572A1 (en) * 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (en) * 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
RU2010153578A (ru) * 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
RU2011104348A (ru) * 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
WO2010095270A1 (ja) 2009-02-23 2010-08-26 株式会社ジーンテクノサイエンス 抗ヒトα９インテグリン抗体とその用途
RU2011148918A (ru) * 2009-05-01 2013-06-10 Эбботт Лэборетриз Иммуноглобулин с двумя вариабельными доменами и его применение
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
JP5781504B2 (ja) * 2009-09-24 2015-09-24 株式会社ジーンテクノサイエンス 細胞外マトリックスタンパク質のアミノ酸配列ｒｇｄに特異的なヒト化抗体およびそれらの使用
AU2010306677B2 (en) * 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20120263722A1 (en) * 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CA2836947A1 (en) * 2011-05-27 2012-12-06 Kalobios Pharmaceuticals, Inc. Anti-emr1 antibodies
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
MX2017001642A (es) * 2014-08-06 2017-04-27 Astellas Pharma Inc ANTICUERPO IGß ANTIHUMANO NOVEDOSO.
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US10349259B2 (en) * 2016-09-23 2019-07-09 Apple Inc. Broadcasting a device state in a wireless communication network
CN114867746A (zh) * 2019-08-09 2022-08-05 小利兰·斯坦福大学董事会 抗骨桥蛋白的治疗性抗体
CN115558015B (zh) * 2022-10-12 2024-01-19 生工生物工程（上海）股份有限公司 一种从gst融合蛋白酶切后的产物中纯化无gst标签的目的蛋白的方法和产品

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US125023A (en) * 1872-03-26 Improvement in sand dredging-machines
US239400A (en) * 1881-03-29 Tobacco-fork
US171358A (en) * 1875-12-21 Improvement in machines for trimming and punching roofing-slates
US1408113A (en) * 1921-01-28 1922-02-28 Mason Richard Colbert Well-measuring device
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU681633B2 (en) 1993-03-11 1997-09-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
EP0705842A2 (en) 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Regulated genes by stimulation of chondrocytes with 1L-1beta
EP0920452A1 (en) 1996-08-22 1999-06-09 Children's Medical Center Corporation Novel osteopontin derived chemotactic peptides and methods of use
WO1998008379A1 (en) 1996-08-27 1998-03-05 Dana-Farber Cancer Institute Methods for identifying modulators of cellular interactions mediated by osteopontin
WO1998056405A1 (en) 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin
AU8783798A (en) 1997-08-15 1999-03-08 Children's Medical Center Corporation Osteopontin coated surfaces and methods of use
CA2251263A1 (en) * 1997-11-14 1999-05-14 Hajime Karasuyama Transgenic animal allergy models and methods for their use
US6414219B1 (en) 1998-06-30 2002-07-02 Rutgers, The State University Of New Jersey Osteopontin knock-out mouse and methods of use thereof
BR0009791A (pt) 1999-04-15 2002-01-08 Childrens Medical Center Métodos para modular, para potencializar e para regular para baixo uma resposta imune de tipo 1 em um paciente, para acentuar a produção de uma citoquina associada com resposta imune de tipo 1, para regular para baixo a produção de uma citoquina associada com resposta imune de tipo 2, para estimular produção de interleucina-12 (il-12) por um macrófago, para inibir a produção de interleucina-10 (il-10) por um macrófago, para a produção de uma molécula, imunomoduladora, e para modular uma resposta imune em uma célula, células de tumor modificadas, e hospedeira, moléculas imunomoduladora biossintética, e de ácido nucleico isolada, vetor de expressão, e, composição farmacêutica
EP1175442A2 (en) 1999-04-15 2002-01-30 Children's Medical Center Corporation Osteopontin-derived chemotactic and inhibitory agents and uses therefor
JP2003528322A (ja) 2000-03-23 2003-09-24 グラクソ グループ リミテッド オステオポンチンのインヒビターのスクリーニング方法
AU1334602A (en) 2000-10-18 2002-04-29 Childrens Medical Center Osteopontin-coated surfaces and methods of use
US20040234524A1 (en) * 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
EP1408113A4 (en) 2001-07-19 2005-01-12 Juridical Foundation HUMAN ANTIHUMAN IGE RECEPTOR ANTIBODY AND ANTIBODY FRAGMENT
CA2461529A1 (en) 2001-09-25 2003-04-03 Immuno-Biological Laboratories Co., Ltd. Recombinant anti-osteopontin antibody and use thereof
WO2003046135A2 (en) 2001-11-21 2003-06-05 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods
CN103518888A (zh) * 2013-10-14 2014-01-22 李民庆 一种养心宁神茶配方

Also Published As

Publication number Publication date
RU2305111C2 (ru) 2007-08-27
JPWO2003027151A1 (ja) 2005-01-06
AU2002332290B2 (en) 2007-11-08
MXPA04002837A (es) 2005-11-04
EP1431310A4 (en) 2005-03-23
US7241873B2 (en) 2007-07-10
NZ531818A (en) 2005-10-28
US20060002923A1 (en) 2006-01-05
WO2003027151A1 (fr) 2003-04-03
BR0213078A (pt) 2004-11-23
PL369446A1 (en) 2005-04-18
HK1084127A1 (en) 2006-07-21
CA2461529A1 (en) 2003-04-03
EP1431310A1 (en) 2004-06-23
CN1688604A (zh) 2005-10-26
NO20041225L (no) 2004-05-25
HUP0402049A3 (en) 2009-04-28
RU2004112540A (ru) 2005-04-20
CN100352844C (zh) 2007-12-05
KR20040048899A (ko) 2004-06-10

Similar Documents

Publication Publication Date Title
HUP0402049A2 (hu) Rekombináns anti-oszteopontin ellenanyag és annak használata
HUP0401561A2 (hu) Anti-oszteopontin ellenanyag és használata
ATE541590T1 (de) Modifizierte antikörper-fragmente
CY1119552T1 (el) Μεθοδος αυξησης της οστικης σκληροτητας και ακαμψιας και μειωσης των καταγματων
NO20060189L (no) Antistoffer mot interleukin-22 og anvendelse derav
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
MX2021015024A (es) Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
NO20053583L (no) Anti-NGF-antistoffer og fremgangsmater for anvendelse av disse
IL165193A0 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
MXPA04001566A (es) Un sistema para expresion y ensamblado de anticuerpos.
TR200202253T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
NO20060843L (no) RG1-antistoffer og anvendelser derav
MY144925A (en) Il-17 antagonistic antibodies
EA201000424A1 (ru) Антитела к il-23
MY141851A (en) Human monoclonal antibodies against human il-4
HUP0202568A2 (hu) VLA-1 elleni blokkoló hatású monoklonális antitest és alkalmazása gyulladásos rendellenességek kezelésére
IL165364A (en) A method for identifying peptides that mimic an autoimmune antibody idiotype associated with autoimmune disease, peptides identified by the above method and their use
HUP0300997A2 (hu) A MIA-fehérje alkalmazása immunterápiában
CY1107785T1 (el) Χρηση του βασιλιξιμαμπ στη θεραπεια της ρευματοειδους αρθριτιδας ´η νοσων του δερματος
ATE389015T1 (de) Paget knochenkrankheit
WO2004087905A3 (en) Protein tyrosine phosphatase and inhibitors thereof
WO2005025618A3 (en) Treatment of rheumatoid arthritis with cd99 antagonists
DE60330780D1 (de) Sequenzen des t-zellrezeptors cdr3 und nachweisverfahren
AU2002342858A1 (en) Human high-affinity antibody fragments for essential proteins of the hepatitis-c virus

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ASTELLAS PHARMA INC., JP

Free format text: FORMER OWNER(S): FUJISAWA PHARMACEUTICAL CO., LTD., JP

Owner name: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD., JP

Free format text: FORMER OWNER(S): FUJISAWA PHARMACEUTICAL CO., LTD., JP

GB9A Succession in title

Owner name: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTI, JP

Free format text: FORMER OWNER(S): IMMUNO-BIOLOGICAL LABORATORIES CO., LTD., JP; FUJISAWA PHARMACEUTICAL CO., LTD., JP

Owner name: ASTELLAS PHARMA INC., JP

Free format text: FORMER OWNER(S): IMMUNO-BIOLOGICAL LABORATORIES CO., LTD., JP; FUJISAWA PHARMACEUTICAL CO., LTD., JP

FD9A Lapse of provisional protection due to non-payment of fees